Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-up of Zuma-1 Cohort 6 (C6)
Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Jaeyeon Kim(Sidney Kimmel Cancer Center), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), Monique C. Minnema(University Medical Center Utrecht), Abhinav Deol(Wayne State University), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Saran Vardhanabhuti, John M. Timmerman(Sheba Medical Center), Catherine Thieblemont(Université Paris Cité), Nancy L. Bartlett(Washington University in St. Louis), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Rhine R. Shen(Broad Institute), Julie M. Vose(University of Nebraska Medical Center), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), André Goy(Hackensack University Medical Center), Yi Lin, Yan Zheng, Umar Farooq(Wake Forest University), Sophie de Guibert(Centre Hospitalier Universitaire de Rennes), Peter A. McSweeney(Mesoblast (United States)), Patrick J. Stiff(Loyola University Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k